Sundar Jagannath, MD
Enriched profileProfessor of Medicine (Hematology and Medical Oncology); Director, Multiple Myeloma Center of Excellence / Network Director, Center of Excellence for Multiple Myeloma · Icahn School of Medicine at Mount Sinai
Sundar Jagannath is Professor of Medicine (Hematology and Medical Oncology); Director, Multiple Myeloma Center of Excellence / Network Director, Center of Excellence for Multiple Myeloma at Icahn School of Medicine at Mount Sinai. OpenAlex indexes 1,113 publications with 63,181 citations (h-index 113); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Sundar Jagannath, MD, is Professor of Medicine (Hematology and Medical Oncology) at Icahn School of Medicine at Mount Sinai / Mount Sinai Tisch Cancer Center. The public record shows 1,113 publications with 63,181 citations (h-index 113), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 16 companies.
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Multiple Myeloma Research and Treatments
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 40 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 483.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma
Sponsor: Jagannath, Sundar, M.D.
Industry payments
Updated 14 Oct 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments
- Janssen Global Services, LLCProgram year20251 payment
- Legend Biotech USA Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
59.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor59.3%Acyclovir100%Part D≥59 patientsAnti-infectives
21.4%Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor11%Entecavir100%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor10.3%Valacyclovir100%Part D<11 patientsCardiovascular
5.5%Bile Acid Sequestrant5.5%Colesevelam Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
213 congress contributions (2004–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
ASCO Annual Meeting
ASCO2025Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.
American journal of hematology
Article2026 - Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.
Bone marrow transplantation
Letter2026 - Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Cancer immunology research
Clinical Trial2026 - Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.
Blood cancer journal
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03An inflammatory cytokine signature predicts COVID-19 severity and survival2,739 citations2020
- 04A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2,642 citations2003
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/profile/Sundar-Jagannath
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - Doximity
doximity.com/pub/sundar-jagannath-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/jagannath-sundar-20b8aba4
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/jagannath-sundar-73768ba3
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- X / Twitter
x.com/Myeloma_Society/status/1707322267103813904
- X / Twitter
x.com/TischCancer/status/1790829719392281057
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
- Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sharecare.com ↗ - Board Certified
Medical Oncology (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sharecare.com ↗
Editorial & leadership roles
journal and society appointments- Senior Editor-in-Chief
Clinical Lymphoma, Myeloma & Leukemia (journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗ - Board Member
International Myeloma Society
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗ - Board Member
Society of Hematologic Oncology (SOHO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
- Michaeli Lifetime Achievement Award for Outstanding Contributions to Multiple Myeloma
SASS-ARENA Foundation for Medical Research
2022provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancerletter.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org ↗
Secondary affiliations
appointments beyond the home institution- Scientific Advisory Board
Caribou Biosciences, Inc.
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →investor.cariboubio.com ↗
Media & interviews
press, podcasts and appearances- Video interview library
VJHemOnc speaker profile featuring multiple recorded interviews on multiple myeloma research/treatment
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗ - Bio and patient-education video content
Patient Power
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →patientpower.info ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Jeffrey Newcorn, MD
Icahn School of Medicine at Mount Sinai
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens